188 related articles for article (PubMed ID: 27286724)
1. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C; Crettol S; Guidi M; Eap CB
Clin Pharmacokinet; 2016 Dec; 55(12):1521-1533. PubMed ID: 27286724
[TBL] [Abstract][Full Text] [Related]
2. A genetic-based population PK/PD modeling of methadone in Chinese opiate dependence patients.
Guo D; Tan Z; Lou X; Shi S; Shu Y; Zhou H; Yu L; Yang H
Eur J Clin Pharmacol; 2022 Apr; 78(4):565-578. PubMed ID: 35013802
[TBL] [Abstract][Full Text] [Related]
3. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
4. Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT).
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):587-596. PubMed ID: 27284701
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2004 Jun; 57(6):742-55. PubMed ID: 15151520
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability of methadone response: impact of genetic polymorphism.
Li Y; Kantelip JP; Gerritsen-van Schieveen P; Davani S
Mol Diagn Ther; 2008; 12(2):109-24. PubMed ID: 18422375
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.
Aruldhas BW; Quinney SK; Overholser BR; Heathman MA; Masters AR; Ly RC; Gao H; Packiasabapathy S; Sadhasivam S
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1183-1194. PubMed ID: 34435753
[TBL] [Abstract][Full Text] [Related]
9. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.
Fonseca F; de la Torre R; Díaz L; Pastor A; Cuyàs E; Pizarro N; Khymenets O; Farré M; Torrens M
PLoS One; 2011 May; 6(5):e19527. PubMed ID: 21589866
[TBL] [Abstract][Full Text] [Related]
11. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Dennis BB; Bawor M; Thabane L; Sohani Z; Samaan Z
PLoS One; 2014; 9(1):e86114. PubMed ID: 24489693
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of methadone and concomitant use of diazepam during methadone maintenance treatment induction: low concentration risk.
Mijatović V; Samojlik I; Petković S; Vukmirović S; Uvelin A; Dickov A
Expert Opin Drug Saf; 2017 Dec; 16(12):1323-1328. PubMed ID: 28934555
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of long QTc interval in methadone maintenance patients.
Fonseca F; Marti-Almor J; Pastor A; Cladellas M; Farré M; de la Torre R; Torrens M
Drug Alcohol Depend; 2009 Jan; 99(1-3):327-32. PubMed ID: 18774239
[TBL] [Abstract][Full Text] [Related]
14. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
15. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
[TBL] [Abstract][Full Text] [Related]
16. Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?
George R; Haywood A; Good P; Hennig S; Khan S; Norris R; Hardy J
Clin Ther; 2017 Sep; 39(9):1840-1848. PubMed ID: 28827023
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosn J Basic Med Sci; 2021 Apr; 21(2):145-154. PubMed ID: 32841585
[TBL] [Abstract][Full Text] [Related]
18. Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.
Stallvik M; Nordstrand B; Kristensen Ø; Bathen J; Skogvoll E; Spigset O
Drug Alcohol Depend; 2013 Apr; 129(1-2):88-93. PubMed ID: 23084592
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 Polymorphisms and Cold Pressor Pain Responses: Opioid-Dependent Patients on Methadone Maintenance Therapy.
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Nurs Res; 2017; 66(2):134-144. PubMed ID: 28252574
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; Dyer KR; White JM; Bochner F
Br J Clin Pharmacol; 2000 Nov; 50(5):427-40. PubMed ID: 11069437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
